Bharat Biotech announced its entry into the Contract Research, Development, and Manufacturing Organisation (CRDMO) space through the establishment of Nucelion Therapeutics Pvt. Ltd. The new wholly-owned subsidiary will focus on providing advanced cell and gene therapy (CGT) development and manufacturing solutions.
Supporting Global Innovators in Next-Generation Therapies
Nucelion Therapeutics partners with global biotech and life sciences companies, offering scalable process development and manufacturing for advanced therapies. The subsidiary operates from a 30,000 sq. ft. GMP-compliant facility in Genome Valley, Hyderabad, capable of producing plasmids, viral and non-viral vectors, cell therapies, and aseptic fill-and-finish products.
Comprehensive Capabilities from Lab to Commercial Scale
Nucelion will offer end-to-end services that span:
- Early-stage clinical development
- Scale-up and process optimization
- Commercial-scale manufacturing
All operations will align with international regulatory frameworks, including US FDA and EMA standards, ensuring global market readiness.
Driving India’s Leadership in Biological Innovation
Dr. Krishna Ella, Founder-Chairman of Bharat Biotech and Non-Executive Director of Nucelion Therapeutics, said, “Pharmaceutical innovation is moving toward biological therapies. We aim to integrate these platforms into India’s healthcare system and ensure equitable access for patients with rare and complex diseases.”
Cell and Gene Therapies Set for Strong Global Growth
Bharat Biotech noted that advances in manufacturing and delivery systems are helping cell therapies evolve into scalable treatment platforms. As reported by msn.com, these developments are expected to expand cell and gene therapies beyond rare diseases into broader oncology, immunology, and regenerative medicine applications.
